Abstract
A large number of markers have been proposed for breast cancer, but among them only CA 15.3, CEA and cytokeratins (i.e. TPA, TPS and Cyfra 21.1) are currently used in clinical practice. Serum marker levels reflect tumour burden, and for this reason they are not sensitive enough to be used for screening and early diagnosis of primary breast cancer. By contrast, the role of tumour markers is established in the diagnosis of recurrent disease and in the evaluation of response to treatment. In the former case, however, prospective randomised studies are required to demonstrate any survival benefit when earlier therapeutic interventions are instituted upon elevation of serum markers. In the second case, tumour marker evaluation represents a simple, objective method for monitoring of therapeutic response that seems to offer significant advantages over conventional imaging methods (e.g., objectivity and modifications in tumour biology). Furthermore, research studies are ongoing to identify and validate new biochemical parameters that can be of use not only in advanced disease, but also in other stages of the diagnostic workup of breast cancer.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Al-Jarallah MA et al (1993) Serum CA 15-3 and CEA patterns in postsurgical follow-up and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. Eur J Surg Oncol 19:74–79
American Society of Clinical Oncology (1996) Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 14:2843–2877
American Society of Clinical Oncology (1998) 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 16:793–795
Arciero C et al (2003) Functional relationship and gene ontology classification of breast cancer biomarkers. Int J Biol Markers 18:241–272
Bast RC et al for the American Society of Clinical Oncology Tumor Markers Expert Panel (2001) Recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 19:1865–1878
Basuyau JP et al (2003) Summary report of the standards, options and recommendations for the use of serum tumour markers on breast cancer: 2000. Br J Cancer 89:532–534
Benchimol S et al (1989) Carcinoembryonic antigen, a human tumor marker, functions as a intercellular adhesion molecule. Cell 57:327–334
Berling B et al (1990) Molecular cloning of a carcinoembryonic antigen (CEA)-gene family-member expressed in leukocytes of chronic myeloid leukemia patients and bone marrow. Cancer Res 50:6534–6539
Bodenmuller H et al (1994) The tumor markers TPA, TPS, TPAcyk and CYFRA 21-1 react differently with the keratins 8, 18 and 19. Int J Biol Markers 9:70–74
Bombardieri E et al (1992) CA 15.3 determination in patients with breast cancer: clinical utility for the detection of distant metastases. Eur J Cancer 294:144–146
Bombardieri E et al (1997) Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer? Eur J Nucl Med 24:1349–1355
Braun S, Naume B (2005) Circulating and disseminated tumor cells. J Clin Oncol 23:1623–1626
Cantwell B et al (1980) Carcino-embryonic antigen assay as a guide to tumour bulk, response to therapy and prognosis in human breast cancer. J Med Sci 149: 469–474
Chan DW et al (1997) Use of truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 15: 2322–2328
Cheung KL et al (2000) Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 26:91–102
Colomer R et al (1989) Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in nonmalignant diseases. Breast Cancer Res Treat 13: 123–133
Colomer R et al (2000) Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 6:2356–2362
Crippa F et al (1992) Single determination of CA 15 and bone scintigraphy in the diagnosis of skeletal metastases of breast cancer. J Nucl Biol Med 36:115–116
Duffy MJ et al (2000) CA 15.3: a prognostic marker in breast cancer. Int J Biol Marker 15:330–333
Duffy MJ (2001) Biochemical markers in breast cancer: which ones are clinically useful? Clin Biochem 34:347–352
Ebeling FG et al (2002) Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer 86:1217–1222
Gaglia P et al (1988) Prognostic value of CEA and ferritin assay in breast cancer: a multivariate analysis. Eur J Cancer Clin Oncol 24:1151–1155
Gion M et al (2001) CA 27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer 37:355–363
Gion M et al (2002) Prognostic role of serum CA 15.3 in 362 node-negative breast cancers: An old player for a new game. Eur J Cancer 38:1181–1188
Gold P, Freedman SO (1965) Demonstration of tumor-specific antigens in human colonic carcinoma by immunological tolerance and absorption techniques. J Exp Med 121:439–562
Guadagni F et al (2001) A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res 7:2357–2362
Hayes DF et al (1985) Use of murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest 75:1671–1678
Hayes DF et al (1986) Comparison of circulating CA 15.3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 10:1542–1550
Hayes DF et al (1988) CA 15.3 and CEA spikes during chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 7:38a
Heer K et al (2001) Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin Cancer Res 7:3491–3494
Hudson MJ et al (2001) Human MUC1 mucin: a potent glandular morphogen. J Pathol 194:373–383
Jäger W et al (1994) Increasing serum tumour markers as decision criteria for hormone-therapy of metastatic breast cancer. Tumor Biol 12:60–66
Jong-Bakker MD et al (1981) Prognostic significance of CEA in breast cancer: a statistical study. Eur J Cancer Clin Oncol 17:1307–1313
Kirnarsky L et al (2000) Structural effects of O-glycosylation on a 15-residue peptide from the mucin (MUC1) core protein. Biochemistry 39:12076–12082
Kokko R et al (2002) CA 15-3 in the follow-up of localized breast cancer: a prospective study. Eur J Cancer 38:1189–1193
Li J et al (2005) Indipendent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 51:2229–2235
Li Y et al (2001) The c-Src tyrosine kinase regulated signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3β and β-catenin. J Biol Chemistry 276:6061–6064
Ligtemberg MJL et al (1992) Suppression of cellular aggregation by high levels of episialin. Cancer Res 52: 2318–2324
Liotta LA, Petricoin EF (2006) Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 116:26–30
Markopoulos CJ et al (1994) CA 15-3 in the prediction of recurrence of breast cancer. Breast Dis 7:1–5
Martinetti A et al (1997) Serum markers of bone metastases in post-menopausal breast cancer patients treated with Formestane. Tumor Biol 18:197–205
Mehta RR et al (1998) Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. J Clin Oncol 16:2409–2416
Molina R, Gion M (1998) Use of blood tumour markers in the detection of recurrent breast cancer. Breast 7:187–189
Molina R et al (2005) Tumor markers in breast cancer-European Group on Tumor Markers recommendation. Tumor Biol 26:281–293
Moll R (1994) Cytokeratins in the histological diagnosis of malignant tumors. Int J Biol Markers 9:63–69
Nagle R (1988) Intermediate filaments: a review of the basic biology. Am J Surg Pathol 12:4–16
Nakata B et al (2000) Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer 89:1285–1290
Nicolini A et al (1991) Evaluation of serum CA 15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer 64:154–158
Nicolini A et al (1997) Prolonged survival by “early” salvage treatment of breast cancer for patients: a retrospective 6-year study. Brit J Cancer 76:1106–1111
Norum LF et al (2001) New immunoassays for MUC1 breast cancer. Tumor Biol 22:216–222
Ogata S et al (1992) Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity. Cancer Res 52:4741–4764
Pegram MD et al (1998) Her-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 52:65–77
Price MR, Tendler JB (1993) Polymorphic epithelial mucins (PEM): molecular characteristic and association with breast cancer. Breast 2:3–7
Quin RJ, McGuckin A (2000). Phosphorylation of the cytoplasmic domain of the MUC1 mucin correlates with changes in cell-cell adhesion. Int J Cancer 87:499–506
Reddish MA et al (1992) Epitope mapping of Mab B27.29 within the protein core of the malignant breast carcinoma-associated mucin antigen MUC1. J Tumor Marker Oncol 7:19–27
Repetto L et al (1993) Serum CEA, CA 15-3 and MCA in breast cancer patients: a clinical evaluation. Cancer Detect Prev 17:411–415
Robertson JFR et al (1999) The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. Eur J Cancer 35:47–53
Rye PD, McGuckin MA (2001) MUC1: antibodies and immunoassays. Tumor Biol 22:269–272
Safi F et al (1989) Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers 4:207–214
Schreiber J et al (2000) Binding of tumor antigen mucin (MUC1) derived peptides to the heat shock protein DnaK. Anticancer Res 20:3093–3098
Schroeder JA et al (2001) Transgenic MUC1 interacts with epidemal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem 276:13057–13064
Seregni E et al (2001) Clinical utility of biochemical markers of bone remodelling in patients with bone metastases of solid tumors. QJ Nucl Med 45:7–17
Smith TJ et al for the American Society of Clinical Oncology Breast Cancer Surveillance Expert Panel (1999) American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 17:1080–1082
Soletormos G et al (1993) A novel method for monitoring high-risk breast cancer with tumor markers: CA 15-3 compared to CEA and TPA. Ann Oncol 4:861–869
Soletormos G et al (1993) Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. Clin Chem 39:2077–2083
Stathopoulos EN et al (2005) Detection of CK-19 mRNA positive cells in peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. Ann Oncol 16:240–246
Stearns V et al (1998) Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res Treat 52:239–259
Steiner PM, Roop DR (1988) Molecular and cellular biology of intermediate filaments. Ann Rev Biochem 57:593–625
Sturgeon C (2002) Practice guidelines for tumor marker use in the clinic. Clin Chem 48:1151–1159
Sundrstrom BE, Stigbrand TI (1994) Cytokeratins and tissue polypepitde antigen. Int J Biol Markers 9:102–108
Taubert H et al (2004) Detection of disseminated tumor cells in peripheral blood of patients with breast cancer: correlation to nodal status and occurrence of metastases. Gyn Oncol 92:256–261
von Mensdorff-Pouilly S et al (2000) Human MUC1 mucin: a multifaceted glycoprotein. Int J Biol Markers 15:343–356
Wang DY et al (1975) Relationship between plasma carcinoembryonic antigen and prognosis in women with breast cancer. Eur J Cancer 11:615–618
Wu JT (2002) c-erbB2 oncoprotein and its soluble ectodomain: a new potential tumor marker for prognosis, early detection and monitoring patients undergoing Herceptin treatment. Clin Chim Acta 322:11–19
Wulfkuhle JD et al (2003) Proteomic application for the early detection of cancer. Nat Rev Cancer 3:267–275
Yasaever V et al (1997) Utility of CA 15.3 in monitoring breast cancer patients with bone metastases: special emphasis on “spiking” phenomenon. Clin Biochem 30:53–56
Yin L et al (2003) Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem 278:35458–35464
Zach O, Lutz D (2006) Tumor cell detection in peripheral blood and bone marrow. Curr Opin Oncol 18:48–56
Zehentner BK et al (2004) Mammoglobin as a novel breast cancer biomarker: multigen reverse transcription-PCR assay and sandwich ELISA. Clin Chem 50:2069–2076
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Seregni, E., Coli, A., Mazzuca, N. (2008). Circulating Tumour Markers in Breast Cancer. In: Bombardieri, E., Gianni, L., Bonadonna, G. (eds) Breast Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-36781-9_4
Download citation
DOI: https://doi.org/10.1007/978-3-540-36781-9_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-36780-2
Online ISBN: 978-3-540-36781-9
eBook Packages: MedicineMedicine (R0)